カテゴリ： GlobalData, イスラエル, 企業調査

BioLineRx Ltd (BLRX)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：BioLineRx Ltd (BLRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9760
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：69
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イスラエル
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
BioLineRx Ltd (BioLineRx) is a clinical stage biopharmaceutical company that focuses on the identification, in-licensing, and development of products to address unmet medical needs. The company focuses mainly on cancer and immunology. Its’s product pipeline includes BL-8040, a short peptide for multiple cancer and hematological indications; BL-5010, a novel medical device for non-surgical removal of skin lesions; and AGI-134 a synthetic alpha-gal immunotherapy for solid tumors. BioLineRx’s pipeline also comprises BL-1230 and BL-9020 in preclinical development. The company in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel. BioLineRx is headquartered in Modi’in, Israel.

BioLineRx Ltd (BLRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BioLineRx Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
BioLineRx Ltd, Medical Devices Deals, 2012 to YTD 2018 10
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Agalimmune Raises USD2 Million in Venture Financing 13
Agalimmune Raises Funds Through Venture Financing Round 14
Private Equity 15
BVF Partners to Invest Additional USD9.6 Million in BioLineRx 15
Partnerships 16
BioLineRx Enters into Agreement with Genentech 16
BioLineRx Forms Joint Venture with I-Bridge Capital 17
BioLineRx to Enter into Agreement with University of Texas MD Anderson Cancer Center 18
BioLineRx Expands Licensing Agreement with Merck 19
BioLineRx Enters into Agreement with Novartis Pharma 20
BioLineRx Enters Into Co-Development Agreement With JHL Biotech 21
Licensing Agreements 23
BioLineRx Enters into Licensing Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem 23
BGN Tech Enters into Licensing Agreement with BioLineRx 24
BioLineRx Enters into Licensing Agreement with Hadassah Medical Organization 25
Agalimmune Enters into Licensing Agreement with KODE Biotech 26
BioLineRx Enters into Licensing Agreement with Omega Pharma for BL-5010 27
BioLineRx Enters Into Licensing Agreement with Jiangsu Chia-tai Tianqing Pharma For BL-8030 28
BioLineRx Enters Into Licensing Agreement With Biokine Therapeutics For BL-8040 29
BioLineRx Enters Into Licensing Agreement With Genoscience Pharma And RFS Pharma For BL-8030 31
BioLineRx Enters into Licensing Agreement for Treatment of Neuropathic Pain 32
University of Massachusetts Medical School Enters Into Licensing Agreement With Agalimmune For Alphaject 33
BioLineRx Enters Into Licensing Agreement With Yissum, B.G. Negev Technologies And Hadasit Medical 34
BioLineRx Enters Into Licensing Agreement With Genoscience For BL-8020 36
Equity Offering 37
BioLineRx to Raise up to USD30 Million in Public Offering of American Depositary Shares 37
BioLineRx Raises USD28.8 Million Public Offering of American Depositary Shares 38
BioLineRx Raises USD28.8 Million in Public Offering of American Depositary Shares 40
BioLineRx to Raise up to USD20 Million in Private Placement of American Depositary Shares 42
BioLineRx Completes Public Offering Of American Depositary Shares For US$24.2 Million 43
BioLineRx Completes Private Placement Of American Depositary Shares For US$8 Million 44
BioLineRx Completes Private Placement Of American Depositary Shares For US$15 Million 45
Acquisition 46
BioLineRx Acquires Agalimmune 46
BioLineRx Ltd – Key Competitors 47
BioLineRx Ltd – Key Employees 48
BioLineRx Ltd – Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Joint Venture 49
Recent Developments 50
Financial Announcements 50
Aug 13, 2018: BioLineRx reports second quarter 2018 financial results 50
May 22, 2018: BioLineRx Reports First Quarter 2018 Financial Results 52
Mar 06, 2018: BioLineRx Reports Year End 2017 Financial Results 54
Nov 21, 2017: BioLineRx Reports Third Quarter 2017 Financial Results 57
Aug 08, 2017: BioLineRx announces Q2 2017 Financial Results 59
May 25, 2017: BioLineRx Reports First Quarter 2017 Financial Results 61
Mar 23, 2017: BioLineRx Reports Year End 2016 Financial Results 63
Clinical Trials 65
May 03, 2017: BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA 65
Mar 20, 2017: BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment 66
Jan 17, 2017: BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA for Pancreatic Cancer 67
Appendix 68
Methodology 68
About GlobalData 68
Contact Us 68
Disclaimer 68

List of Tables
BioLineRx Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BioLineRx Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BioLineRx Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
BioLineRx Ltd, Medical Devices Deals, 2012 to YTD 2018 10
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Agalimmune Raises USD2 Million in Venture Financing 13
Agalimmune Raises Funds Through Venture Financing Round 14
BVF Partners to Invest Additional USD9.6 Million in BioLineRx 15
BioLineRx Enters into Agreement with Genentech 16
BioLineRx Forms Joint Venture with I-Bridge Capital 17
BioLineRx to Enter into Agreement with University of Texas MD Anderson Cancer Center 18
BioLineRx Expands Licensing Agreement with Merck 19
BioLineRx Enters into Agreement with Novartis Pharma 20
BioLineRx Enters Into Co-Development Agreement With JHL Biotech 21
BioLineRx Enters into Licensing Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem 23
BGN Tech Enters into Licensing Agreement with BioLineRx 24
BioLineRx Enters into Licensing Agreement with Hadassah Medical Organization 25
Agalimmune Enters into Licensing Agreement with KODE Biotech 26
BioLineRx Enters into Licensing Agreement with Omega Pharma for BL-5010 27
BioLineRx Enters Into Licensing Agreement with Jiangsu Chia-tai Tianqing Pharma For BL-8030 28
BioLineRx Enters Into Licensing Agreement With Biokine Therapeutics For BL-8040 29
BioLineRx Enters Into Licensing Agreement With Genoscience Pharma And RFS Pharma For BL-8030 31
BioLineRx Enters into Licensing Agreement for Treatment of Neuropathic Pain 32
University of Massachusetts Medical School Enters Into Licensing Agreement With Agalimmune For Alphaject 33
BioLineRx Enters Into Licensing Agreement With Yissum, B.G. Negev Technologies And Hadasit Medical 34
BioLineRx Enters Into Licensing Agreement With Genoscience For BL-8020 36
BioLineRx to Raise up to USD30 Million in Public Offering of American Depositary Shares 37
BioLineRx Raises USD28.8 Million Public Offering of American Depositary Shares 38
BioLineRx Raises USD28.8 Million in Public Offering of American Depositary Shares 40
BioLineRx to Raise up to USD20 Million in Private Placement of American Depositary Shares 42
BioLineRx Completes Public Offering Of American Depositary Shares For US$24.2 Million 43
BioLineRx Completes Private Placement Of American Depositary Shares For US$8 Million 44
BioLineRx Completes Private Placement Of American Depositary Shares For US$15 Million 45
BioLineRx Acquires Agalimmune 46
BioLineRx Ltd, Key Competitors 47
BioLineRx Ltd, Key Employees 48
BioLineRx Ltd, Subsidiaries 49
BioLineRx Ltd, Joint Venture 49

List of Figures
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
BioLineRx Ltd, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[BioLineRx Ltd (BLRX)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Warner Media LLC.：企業の戦略・SWOT・財務情報
    Warner Media LLC. - Strategy, SWOT and Corporate Finance Report Summary Warner Media LLC. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Sherwin-Williams Co (SHW)：企業の財務・戦略的SWOT分析
    Sherwin-Williams Co (SHW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Mosenergo (MSNG)：電力：M&Aディール及び事業提携情報
    Summary Mosenergo, a subsidiary of Gazprom Energoholding LLC, is a power utility. It generates electricity and thermal energy using natural gas, coal, fuel oil, and diesel sources. The company owns and operates power plants: TPP-20, SDPP-3, TPP-9, SPP-1, TPP-21, TPP-8, TPP-11, TPP-16, TPP-12, TPP-17 …
  • Esperion Therapeutics Inc (ESPR)：製薬・医療：M&Aディール及び事業提携情報
    Summary Esperion Therapeutics Inc (Esperion), a subsidiary of Pfizer Inc is a pharmaceutical company that develops and commercializes once-daily, oral and low-density lipoprotein cholesterol lowering therapies. The company develops oral therapies to treat patients with elevated low-density lipoprote …
  • Senior Lifestyle Corp：製薬・医療：M&Aディール及び事業提携情報
    Summary Senior Lifestyle Corp (Senior Lifestyle) is a healthcare service provider that provides healthcare and resident services. The company owns and operates several senior living apartments and retirement communities. It provides life enrichment programs such as cultural and social activities, tr …
  • Progenity Inc：医療機器：M&Aディール及び事業提携情報
    Summary Progenity, Inc. (Progenity) is a US based company engaged in providing specialized diagnostic and complex molecular tests to clinicians. The company offers molecular and diagnostic testing for inheritable cancer, pre-eclampsia and genetic disorders to children and women. It also provides ser …
  • Maquet Holding BV & Co KG：医療機器：M&Aディール及び事業提携情報
    Summary Maquet Holding BV & Co KG (Maquet), a subsidiary of Getinge AB, designs, develops and sells medical systems. The company’s major products include anesthesia delivery systems, surgical assist systems, fixed equipment, mobile equipment, operation room lights and ceiling supply units, vascular …
  • Pricer AB (PRIC B)：企業の財務・戦略的SWOT分析
    Pricer AB (PRIC B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Arcbest Corp.
    Arcbest Corp. - Strategy, SWOT and Corporate Finance Report Summary Arcbest Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Molex LLC-医療機器分野：企業M&A・提携分析
    Summary Molex LLC (Molex), a subsidiary of Koch Industries, is a US-based manufacturer of electronic components. The company principally focuses on manufacturing and sale of electronic, electrical and fiber optic interconnection systems. Molex's product portfolio includes switches, integrated produc …
  • Pan Malaysia Holdings Berhad：企業の戦略・SWOT・財務分析
    Pan Malaysia Holdings Berhad - Strategy, SWOT and Corporate Finance Report Summary Pan Malaysia Holdings Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • GenomicTree Inc：企業の製品パイプライン分析2018
    Summary GenomicTree Inc (GenomicTree) is a medical device company that develops and commercializes diagnostic products for the screening and diagnosis of cancer. The company also provides non-invasive cancer molecular diagnostic product. Its products are used in the detection of colorectal, lung and …
  • MTS Systems Corp (MTSC)：企業の財務・戦略的SWOT分析
    Summary MTS Systems Corp (MTS) is an industrial equipment supplier that offers testing and sensing solutions. The company’s products include test components, actuators and hydraulic components, controllers, grips, fixtures and accessories, hydraulic power and distribution; environmental simulation s …
  • Putnam Investments LLC：企業の戦略的SWOT分析
    Putnam Investments LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Toro Energy Ltd (TOE)：企業の財務・戦略的SWOT分析
    Toro Energy Ltd (TOE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Abreos Biosciences Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Abreos Biosciences Inc (Abreos) is a biotechnology company with focus on the development of laboratory-based and point-of-care (POC) assays and reagents for the precision dose monitoring of biologic drugs. Its Monator, is a drug-monitoring test that provides physicians with vital information …
  • Universities Superannuation Scheme Ltd：企業の戦略的SWOT分析
    Universities Superannuation Scheme Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • Active Implants LLC：医療機器：M&Aディール及び事業提携情報
    Summary Active Implants LLC (Active Implants), formerly Active Implants Corp is a medical equipment provider that develops orthopedic equipment. The company develops and commercializes polymer orthopedic implant solutions which include tribofit hip system, tribofit instrumentation equipment, NuSurfa …
  • Australian Mines Limited：企業の戦略・SWOT・財務情報
    Australian Mines Limited - Strategy, SWOT and Corporate Finance Report Summary Australian Mines Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Swadeshi Industrial Works Plc：企業の戦略・SWOT・財務情報
    Swadeshi Industrial Works Plc - Strategy, SWOT and Corporate Finance Report Summary Swadeshi Industrial Works Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆